| 30.04.2024 19:54 | TAND, IGE, CHL | EARNINGS AND TRADING: Software Circle & Beximco report higher revenue | Alliance |
| 30.04.2024 07:00 | STX | Business Update for Q1 2024 | RNS |
| 23.04.2024 14:26 | WTB, ROR, SAFE | UK earnings, trading statements calendar - next 7 days | Alliance |
| 16.04.2024 07:00 | STX | Notice of Results | RNS |
| 21.02.2024 12:36 | STX | Shield Therapeutics sinks as strong performance marred by data issues | Alliance |
| 21.02.2024 07:00 | STX | Unaudited Full Year Trading Update | RNS |
| 09.01.2024 11:33 | STX | IN BRIEF: Shield Therapeutics hires former Akili leader as new CFO | Alliance |
| 09.01.2024 07:00 | STX | Appointment of new Chief Financial Officer | RNS |
| 07.12.2023 15:31 | COM, IGP, WSP | TRADING UPDATES: Comptoir opens restaurant; Intercede wins contract | Alliance |
| 07.12.2023 07:00 | STX | Q3 2023 U.S. Commercial Highlights | RNS |
| 27.11.2023 17:24 | STX | PDMR Transaction Notification | RNS |
| 15.11.2023 07:30 | STX | Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team | EQS |
| 20.10.2023 11:45 | STX | Abstract to be presented at Healthcare Conference | Reach |
| 12.10.2023 11:14 | STX | IN BRIEF: Shield Therapeutics Chief Financial Officer Rudolf to leave | Alliance |
| 12.10.2023 10:27 | WNWD, NBB, STX | AIM WINNERS & LOSERS: Windward sees high contracting activity levels | Alliance |
| 12.10.2023 07:00 | STX | Chief Financial Officer Transition | RNS |
| 03.10.2023 17:14 | STX, AML, ANGS | TRADING UPDATES: Aston Martin CEO ups stake; Alkemy's lithium deal | Alliance |
| 03.10.2023 15:00 | STX | Result of REX Retail Offer | RNS |
| 03.10.2023 14:29 | STX | Shield Therapeutics completes USD20 million SWK financing | Alliance |
| 03.10.2023 07:00 | STX | Block listing Interim Return | RNS |
| 03.10.2023 07:00 | STX | Completion of SWK Financing | RNS |
| 28.09.2023 14:54 | STX | UPDATE: Shield Therapeutics completes GBP5 million share placing | Alliance |
| 28.09.2023 12:50 | STX | Successful completion of US$6.1m Equity Fundraise | RNS |
| 28.09.2023 11:30 | STX | Shield Therapeutics raises funds for US sales push as loss narrows | Alliance |
| 28.09.2023 07:02 | STX | REX Retail Offer | RNS |
| 28.09.2023 07:01 | STX | $20m secured debt facility &proposed equity raise | RNS |
| 28.09.2023 07:00 | STX | Interim results update and business update | RNS |
| 21.09.2023 15:48 | XLM, TRIN, TRLS | UK earnings, trading statements calendar - next 7 days | Alliance |
| 06.09.2023 20:33 | STX | IN BRIEF: Shield Therapeutics changes reporting currency to US dollars | Alliance |
| 06.09.2023 07:00 | STX | Notice of Results and Change in reporting currency | RNS |
| 25.07.2023 09:45 | STX | Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering | EQS |
| 24.07.2023 14:27 | JUP, STX | Holding(s) in Company | RNS |
| 20.07.2023 11:43 | STX | IN BRIEF: Shield Therapeutics prescription orders up in first quarter | Alliance |
| 20.07.2023 07:00 | STX | Business Update and U.S. Q2 2023 Highlights | RNS |
| 28.06.2023 17:30 | STX | Results of 2023 Annual General Meeting | RNS |
| 21.06.2023 15:43 | ZED, WSG, W7L | UK shareholder meetings calendar - next 7 days | Alliance |
| 16.06.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 15.06.2023 16:35 | STX | Lapse of Offer | RNS |
| 15.06.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 15.06.2023 07:00 | STX | Acceptance Level Update | RNS |
| 14.06.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 14.06.2023 07:00 | STX | Acceptance Level Update | RNS |
| 13.06.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 13.06.2023 07:00 | STX | Acceptance Level Update | RNS |
| 12.06.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 12.06.2023 07:00 | STX | Acceptance Level Update | RNS |
| 09.06.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 09.06.2023 07:00 | STX | Acceptance Level Update | RNS |
| 08.06.2023 12:31 | STX | Form 8.3 - Shield Therapeutics PLC (amendment) | RNS |
| 08.06.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 08.06.2023 07:00 | STX | Acceptance Level Update | RNS |
| 07.06.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 06.06.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 06.06.2023 10:10 | STX | Grant of share options to the CEO | RNS |
| 05.06.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 02.06.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 01.06.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 01.06.2023 11:00 | STX | Holding(s) in Company | RNS |
| 01.06.2023 10:55 | STX | Holding(s) in Company | RNS |
| 31.05.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 31.05.2023 07:00 | STX | Total Voting Rights | RNS |
| 30.05.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 26.05.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 25.05.2023 16:44 | STX | Publication and posting of Offer Document | RNS |
| 25.05.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 24.05.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 23.05.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 22.05.2023 13:25 | STX | Form 8.3 - Shield Therapeutics PLC | RNS |
| 19.05.2023 16:17 | STX | Form 8.3 - Shield Therapeutics Plc | RNS |
| 19.05.2023 14:29 | STX | Form 8.3 – Shield Therapeutics plc | RNS |
| 18.05.2023 15:15 | STX | Form 8 (OPD) - Shield Therapeutics plc | RNS |
| 18.05.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 17.05.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
| 17.05.2023 07:15 | STX | Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptions | EQS |
| 16.05.2023 12:00 | STX | Form 8.5 (EPT/RI) - Shield Therapeutics Plc | RNS |
